首页|期刊导航|实用心脑肺血管病杂志|同型半胱氨酸与心脑血管疾病的关系及其干预界值争议

同型半胱氨酸与心脑血管疾病的关系及其干预界值争议OA

Relationship between Homocysteine and Cardiovascular and Cerebrovascular Diseases and Its Intervention Threshold Controversy

中文摘要英文摘要

在我国,H型高血压(高血压合并高同型半胱氨酸血症)患者占高血压总人数的75%,该病是脑卒中首要可控危险因素,但同型半胱氨酸(Hcy)的最佳干预界值尚未达成共识.基于此,本文整合现有研究证据,综述了Hcy与心脑血管疾病的关系并深入分析Hcy干预界值争议,发现Hcy升高作为心脑血管疾病的独立危险因素,与心脑血管疾病风险及不良预后相关,且Hcy不同程度升高对心脑血管疾病预后的影响不同.目前,全球主要学术机构对Hcy干预界值持有不同观点,有支持Hcy较高干预界值(15 μmol/L)的,也有支持Hcy较低干预界值(10 μmol/L)的,还有支持Hcy其他干预界值的.

In China,the number of patients with H-type hypertension(hypertension combined with hyperhomocysteinemia)accounts for 75%of the total number of patients with hypertension,and the disease is the primary controllable risk factor for stroke.However,the optimal intervention threshold of homocysteine(Hcy)has not yet reached a consensus.Based on this,this paper integrates the existing research evidence,and reviews the relationship between Hcy and cardiovascular and cerebrovascular diseases and deeply analyzes the controversy of Hcy intervention threshold.It finds that elevated Hcy levels serve as an independent risk factor for cardiovascular and cerebrovascular diseases,correlating with disease risk and adverse outcomes,with varying impacts on prognosis depending on the degree of Hcy elevation.Currently,major academic institutions worldwide hold differing views on Hcy intervention thresholds,with some supporting a higher threshold(15 μmol/L),others advocating for a lower threshold(10 μmol/L),and still others proposing alternative thresholds.

陈源源

100044 北京市,北京大学人民医院高血压科

医药卫生

心血管疾病脑血管障碍同型半胱氨酸干预界值争议

Cardiovascular diseasesCerebrovascular disordersHomocysteineIntervention thresholdControversy

《实用心脑肺血管病杂志》 2026 (5)

1-6,6

10.12114/j.issn.1008-5971.2026.00.112

评论